IBJNews

Group aims to cut costs of late-stage drugs

Back to TopCommentsE-mailPrintBookmark and Share

You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help.

But that’s exactly what happened last week when 10 major drug companies—including Indianapolis-based Eli Lilly and Co.—joined forces to cut costs out of clinical trials.

The 10 companies formed a not-for-profit organization called TransCelerate BioPharma Inc. Each company is contributing roughly a dozen employees to the project, as well as an undisclosed amount of money.

TransCelerate has a list of about 50 projects to work on to cut unnecessary costs from Phase 2 and Phase 3 clinical trials. Those two stages of human testing cost nearly $150 million per drug, according to studies by the Tufts Center for the Study of Drug Development.

“It’s significant,” said Jeff Kasher, vice president of Lilly’s Development Center of Excellence in Indianapolis, of the potential cost savings of the effort. He declined to quantify the expected savings, but he added, “I’m really, really confident that we’re going to deliver the goods from this group.”

TransCelerate has an initial three-year goal to show time and dollar savings in five areas. They include establishing a common supply model for comparison drugs—the existing medicines that experimental drugs are often tested against.

Also, TransCelerate plans to develop a common computer interface for physicians and their staffs conducting drug trials, which would recognize which companies and which drugs that particular medical center is doing work for and grant computer access to only those trials.

TransCelerate also intends to develop a new approach to monitoring the various sites that conduct clinical trials. Currently, some drug companies require extensive paper documentation of every aspect of a clinical trial while others do random sampling to generate statistics, which they use to monitor the clinical trial sites.

But TransCelterate will try to unite all 10 drug companies under a “risk-based monitoring approach” that documents aspects of drug trials that will be key in the regulatory review of the drug and pays less attention to less-critical areas.

“Everybody does it differently. Nobody really does it all that better than anybody else. But because we do it differently, we create confusion for a lot of the research sites,” Kasher said.

The 10 companies participating in TransCelerate are Lilly; Illinois-based Abbott Laboratories; United Kingdom-based AstraZeneca plc; Germany-based Boehringer Ingelheim GmbH; New York-based Bristol-Myers Squibb Co.; United Kingdom-based GlaxoSmithKline plc; New Jersey-based Johnson & Johnson; New York-based Pfizer Inc.; Genentech Inc.; which is a subsidiary of the Switzerland-based Roche Group; and France-based Sanofi-Aventis SA.

Many of them have struggled recently to launch enough new drugs to offset declining sales after their older blockbusters' patents expire. Lilly is in the midst of a four-year run in which it will see patents on five blockbusters expire, sapping as much as $10 billion in annual revenue.

Lilly has pushed more than 60 new drugs into experimental trials, but the cost of testing all of those in humans is pinching the company’s profits. A similar story is playing out at many of its competitors’.

“Even five years ago, this wouldn’t have happened,” Kasher said. “I’d say there’s frustration across the industry and pressure across the industry to accelerate the development of innovative medicines.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT